Not Yet Recruiting PHASE2 INTERVENTIONAL 1-arm NCT05151588

Induction Chemotherapy and Tazemetostat for Locally Advanced SMARCB1-deficient Sinonasal Carcinoma

A Phase II Single-arm Study of Tazemetostat With Docetaxel, Cisplatin, and 5-fluorouracil as Preoperative Treatment for Locally Advanced Potentially Resectable SMARCB1 (INI-1)- Deficient Sinonasal Carcinoma

Sponsor: Dr. Victor H.F. Lee

Conditions Sinonasal Carcinoma

Interventions 5-FU Chemoradiation Cis Platinum Docetaxel Surgery Tazemetostat

Updated 4 times since 2022 Last updated: Feb 26, 2023 Started: Sep 1, 2023 Primary completion: Aug 31, 2026 Completion: Aug 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Sinonasal Carcinoma and is currently actively recruiting participants. Dr. Victor H.F. Lee leads this study, which shows 4 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Mar 2023 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2
Jan 2022 — Mar 2023 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dr. Victor H.F. Lee

Data source: The University of Hong Kong

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.